Effective treatment of ultra-rare diseases begins with understanding their biology and adopting an integrated research approach. By combining multidimensional cellular measurements — from metabolism and proteomics to cell signaling and immune responses — we can build a precise picture of the pathogenic mechanisms underlying CFC4. This foundation is essential for developing more effective targeted therapies, biomarkers for monitoring treatment, new clinical guidelines, and, in the future, gene therapy and disease-modifying drugs.
Biomarker Research
One of the key goals of our work is to identify biomarkers that may reflect disease activity and the cellular disturbances caused by MEK2 mutations. We analyze blood samples to assess levels of cytokines, inflammatory proteins, and molecules involved in cell–cell communication. This multiparametric approach allows us to capture subtle changes in the functioning of the immune system, nervous system, and vascular tissues.
Using panels that measure markers of neuroinflammation, immune activation, vascular inflammation, and cell adhesion, we can determine which processes are most disrupted in individuals with CFC4. These molecules may become future diagnostic markers for conditions observed in CFC. Biomarker research not only helps us understand the dynamics of the disease but also allows us to monitor its progression and evaluate the effectiveness of emerging treatments.
Mitochondrial Research
The second pillar of our work involves mitochondrial studies conducted on fibroblasts obtained from patients. Mitochondria play a central role in energy production, metabolic regulation, and cellular stress responses. Mutations in MAPK–ERK pathway genes (such as MEK2) can potentially impair mitochondrial function, leading to bioenergetic disturbances and increased vulnerability to cellular damage.
In our research, we analyze the proliferative potential of cells, their metabolic profile, and the proteomic composition of the respiratory chain. Comparing patient-derived fibroblasts with control lines allows us to identify which bioenergetic pathways are dysfunctional and which mitochondrial proteins are altered. Together, these measurements form a “multiparametric cellular signature” — a unique profile that distinguishes patient cells from healthy ones.
This integrated approach not only deepens our understanding of CFC4 pathophysiology but also helps identify potential therapeutic strategies that could prevent cellular degeneration or improve mitochondrial and metabolic function.


